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Abstract
Ten years after the discovery of spirochaetes as agents of Lyme disease in 1982 in the USA, three genomic species had diverged from
the phenotypically heterogeneous strains of Borrelia burgdorferi isolated in North America and Europe: Borrelia afzelii, B. burgdorferi sen-
su stricto (further B. burgdorferi), and Borrelia garinii. Whereas B. burgdorferi remained the only human pathogen in North America, all
three species are aetiological agents of Lyme borreliosis in Europe. Another seven genospecies were described in the 1990s, including
species from Asia (Borrelia japonica, Borrelia turdi, and B. tanukii), North America (Borrelia andersonii), Europe (Borrelia lusitaniae and Bor-
relia valaisiana), and from Europe and Asia (Borrelia bissettii). Another eight species were delineated in the years up to 2010: Borrelia sinica
(Asia), Borrelia spielmanii (Europe), Borrelia yangtze (Asia), Borrelia californiensis, Borrelia americana, Borrelia carolinensis (North America),
Borrelia bavariensis (Europe), and Borrelia kurtenbachii (North America). Of these 18 genomic species B. afzelii, B. burgdorferi and B. garinii
are the conﬁrmed agents of localized, disseminated and chronic manifestations of Lyme borreliosis, whereas B. spielmanii has been
detected in early skin disease, and B. bissettii and B. valaisiana have been detected in specimens from single cases of Lyme borreliosis.
The clinical role of B. lusitaniae remains to be substantiated.
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Introduction
Lyme borreliae may be considered postmodern pathogens,
because the illness they cause varies, does not have a pre-
dictable incubation period or course, and is likely to have a
variable response. Protean manifestations and the absence of
techniques to identify the organism in cases of Lyme borre-
liosis lead to bizarre ideas, and fantasies [1–3].
From Lyme Spirochaete to Borrelia
burgdorferi Sensu Lato
In 1982, after the discovery of Lyme spirochaetes in hard ticks
from Long Island, NY, USA [4], the aetiology of Lyme disease
was conﬁrmed by the cultivation of these spirochaetes from
skin, blood and cerebrospinal ﬂuid (CSF) of patients [5,6]. The
Lyme spirochaete was identiﬁed as a new species of the genus
Borrelia [7]. It very quickly became evident that not only did
the clinical presentation of a Borrelia burgdorferi infection in
Europe differ somewhat from that in North America, but so
did the isolates from Lyme borreliosis patients and from ticks
[8–10]. It was observed that an increasing number of Euro-
pean isolates of Lyme borreliae from patients and ticks were
phenotypically heterogeneous and differed from the American
type strain of B. burgdorferi. Thus, it was concluded that
B. burgdorferi may comprise different genomic species, which,
however, share common epitopes that are recognized by cer-
tain monoclonal antibodies. A serotyping system based on
monoclonal antibody reactivity against the outer surface pro-
tein OspA was introduced. At the subspecies level, heteroge-
neity was demonstrated by restriction endonuclease analysis,
hybridization with whole B. burgdorferi DNA or speciﬁc
probes, and plasmid analysis. Genetic analysis of the broad
variety of phenotypically deﬁned strains was required in order
to identify genotypic clusters [11]. The ﬁrst result of an
approach to classify Lyme borreliae on the basis of genomic
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criteria was the delineation of three DNA groups, namely of
genospecies B. burgdorferi sensu stricto (further B. burgdorferi),
Borrelia garinii sp. nov., and group VS461; all of these strains
were associated with clinical Lyme borreliosis [12]. In a similar
study, genomic ﬁngerprinting by an arbitrarily primed PCR
with Borrelia isolates predominantly from Ixodes species and
mice from North America, Europe and Japan delineated three
Borrelia groups [13]. These results were in complete agree-
ment with the results of the previously cited study [12]. How-
ever, two isolates were distinct from all of the other strains in
the collection but were clearly members of the genus Borrelia
[13]. Later, group VS461 strains were identiﬁed with mono-
clonal antibodies and named Borrelia afzelii. On the basis of a
small number of Borrelia isolates from the skin of patients suf-
fering from acrodermatitis chronica atrophicans, a skin mani-
festation of European Lyme borreliosis, but also recovered
from erythema migrans, it was stated that B. afzelii sp. nov. is
the only member of this group to result in acrodermatitis
chronica atrophicans [14].
Expansion of the Lyme Borrelia Complex
during the 1990s
Genomic ﬁngerprinting of B. burgdorferi sensu lato strains by
pulsed-ﬁeld gel electrophoresis (PFGE) showed that all iso-
lates used in this study were recognized by one band
(135 kbp), each of the B. garinii isolates by two bands (220
and 80 kbp), and each of the B. afzelii isolates by three bands
(460, 320 and 90 kbp). Whilst there were differences in the
PFGE patterns among B. burgdorferi and B. garinii isolates, the
patterns of B. afzelii isolates were all similar [15]. The number
of genomic species was further expanded by the characteriza-
tion of borreliae isolated from Ixodes ovatus ticks in Japan. A
new species, apparently not a human pathogen and restricted
to Japan [16], was hence named Borrelia japonica [17]. Another
study focused on the ribosomal genes of B. burgdorferi [18],
using restriction polymorphism analysis of PCR products
obtained with primers at the 3¢-end of the ﬁrst rrf gene and at
the 5¢-end of the second rrl gene. An amplicon, 226–266 bp in
length, was generated from the B. burgdorferi strains tested.
Restriction polymorphism analysis of the resulting amplicons
with the nuclease MseI permitted identiﬁcation of the estab-
lished species B. burgdorferi, B. garinii, B. afzelii, and B. japonica
(formerly group F63B), and the identiﬁcation of four new
genomic groups. Two of these genomic groups were Euro-
pean strains, and the other two were North American strains.
The method developed in that study could be applied for
rapid screening of strain collections and for epidemiological
and medical purposes [19]. With a similar approach, a new
species, named Borrelia andersonii, was identiﬁed [20]. Geno-
mic typing of borrelial strains isolated from Ixodes tanuki and
Ixodes turdus ticks in Japan revealed two new genospecies,
named Borrelia tanukii and Borrelia turdi [21].
Some researchers recognized the greater variety of B. burg-
dorferi, the sole North American aetiological agent of Lyme
borreliosis, which is also present in Europe. The multiplicity
of genospecies in Europe might indicate that Lyme borreliae
emerged in Europe. However, according to ospC typing, there
was a closer relationship between the European strains than
between those in North America, supporting the reverse
conclusion, that B. burgdorferi was introduced to Europe from
America [22,23]. Despite this, a different view on the origin
of B. burgdorferi has recently been published [24].
Nevertheless, more genospecies were described. Borrelia
strains isolated from Ixodes ricinus ticks in Switzerland, The
Netherlands, and the UK of genomic groups VS116 and M19
were carefully characterized, and their taxonomic status was
assessed; as a result of this, new genospecies was proposed,
Borrelia valaisiana sp. nov., type strain VS116 [25].
Isolates of another genomic species, PotiB2, isolated from
I. ricinus ticks in Portugal, were studied in detail, and this
resulted in the proposal of a new species, Borrelia lusitaniae,
type strain PotiB2 [26].
Not only was diversity among European Borrelia strains
being being re-examined, but atypical strains of North Amer-
ican origin, previously designated genomic group DN127,
were closely analysed, and it was found that they cluster sep-
arately from B. burgdorferi. The conclusion was that genomic
group DN127 should be referred to as a new species, Bor-
relia bissettii sp. nov., and that other related but distinct
strains, which require further characterization, should be
referred to as Borrelia spp. [27].
Up to this point, ten species within the B. burgdorferi sen-
su lato complex have been recognized, but only three—
B. afzelii, B. burgdorferi, and B. garinii—were widely accepted
human pathogens. These pathogenic Borrelia species were
characterized by their vectors, geographical distribution, and
organotropism [28].
Expansion of the Lyme Borrelia Complex in
the New Millenium
The newly described genospecies B. valaisiana, a Borrelia spe-
cies isolated from I. ricinus ticks in some countries of Europe
[25], was also identiﬁed in specimens from wild rodents cap-
tured on Kinmen Island and from central Taiwan [29]. Borr-
eliae were also isolated from rodents and ixodid ticks
collected in southern China. Molecular characterization of
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these isolates from white-bellied rats (Niviventer confucianus)
and from Ixodes ovatus ticks revealed sufﬁcient diversity to
justify a new species, Borrelia sinica sp. nov., type
strain CMN3T [30]. Meanwhile, analysis of B. lusitaniae iso-
lates from North Africa, Tunisia and Morocco revealed only
moderate diversity, suggesting that B. lusitaniae isolates from
North Africa constitute a clone of Portuguese origin [31].
Garden dormice were found to be the reservoir hosts of a
novel Borrelia species. Its unique biological relationship,
together with previous genetic characterization, justiﬁed des-
ignating this dormouse-associated genospecies as a distinct
entity, Borrelia spielmani sp. nov., which is considered to be a
human pathogen, as it was isolated from patients in central
Europe [32]. When those strains were further characterized,
the novelty was conﬁrmed, and the spelling of the name was
corrected to Borrelia spielmanii, type strain PC-Eq17N5T
[33]. It was further shown that B. spielmanii resists human
complement-mediated killing by direct binding of the immune
regulators factor H and factor H-like protein 1 [34].
By multilocus sequence analysis (MLSA), ﬁve B. valaisiana-
related strains isolated from rodents and ticks in southwest-
ern China were eventually classiﬁed as a new genospecies of
B. burgdorferi sensu lato rather than B. valaisiana; these strains
were named Borrelia yangtze [35]. MLSA clariﬁed our under-
standing of the taxonomy of B. burgdorferi sensu lato, by
replacing the cumbersome DNA–DNA hybridization method.
With this method, a new North American genospecies was
delineated, and named Borrelia californiensis [36].
In 2009, another three novel species, two from North
America and one from Europe, were delineated by MLSA:
Borrelia americana, Borrelia carolinensis, and Borrelia bavariensis,
respectively. The ﬁrst genospecies resulted from analyses of
isolates from nymphal Ixodes minor ticks collected in South
Carolina, and showed close relatedness to California strains
known as genomospecies 1, associated with Ixodes paciﬁcus
[37]. The second resulted from the phylogenetic analysis of
isolates from rodents from North Carolina, and was there-
fore named B. carolinensis [38]. A formal description of B. car-
olinensis sp. nov., type strain SCW-22T, isolated from
rodents and ticks from the southeastern USA, followed [39].
The description of the third novel genospecies resulted from
analysis of the rodent-associated ecotypes of B. garinii, OspA
serotype 4 strains [40], which were sufﬁciently genetically
distinct from bird-associated B. garinii strains. Thus, it was
concluded that this distinction deserves species status, and
the name B. bavariensis sp. nov. was suggested [41].
MLSA of the phylogenetic relationships of North Ameri-
can B. bissettii disclosed a cluster of strains that were more
distant from B. bissettii than B. carolinensis, with the proposi-
tion that these constitute a new Borrelia genospecies. The
name Borrelia kurtenbachii sp. nov. was suggested, in honour
of the late Klaus Kurtenbach [42]. Fig. 1 shows the increasing
numbers of genospecies deﬁned within the 28 years after the
discovery of the ‘Lyme spirochaete’.
Methods used for the Identiﬁcation of
Novel Borrelia genospecies
The method of whole DNA–DNA hybridization (WDDH) still
represents the reference standard for species delineation
[33,43]. According to Wayne et al. [43], DNA relatedness
above 70% and a DTm below 5C are the basic characteristics
within a phylogenetic species. Large restriction fragment length
polymorphism analysis with MluI digestion of Borrelia genomic
DNA followed by subsequent resolution of the fragments by
PFGE provides an alternative to the WDDH approach, and
allows for species and strain determination [15,44]. Cultivabil-
ity, however, is a prerequisite for both of the above tech-
niques, and in addition to this, the application of WDDH for
slow-growing bacteria is limited [33]. However, isolation
introduces a selection bias, as not all strains grow equally well
in culture [45]. To circumvent these problems, improved high-
resolution typing methods have been applied to the borreliae.
PCR-based restriction fragment length polymorphism (RFLP)
has been shown to be an exceptionally valuable method for
species and even subspecies discrimination [46]. RFLP of the
5S (rrfA)–23S (rrlB) intergenic spacer region, as described by
Postic et al., has been extensively used as a fast and simple
method for molecular typing of Borrelia species [19,47,48].
RFLP of the 16S (rrs)–23S (rrlA) intergenic spacer region,
although this region is less diverse, presently allows the char-
acterization of three different ribosomal spacer types (RSTs)
[49,50]. In addition to the use of RSTs to explore phylogenetic
relationships, correlations of certain subtypes with differences
in virulence and ability to disseminate have been described
[51,53]. Furthermore, RSTs are in strong, although spatially
restricted [54], linkage disequilibrium with ospC, another mar-
ker that is frequently used in both classic serotyping and geno-
typing of Borrelia [52,55]. As sequence-based methods have
largely replaced other methods for microbial population analy-
sis [56], Richter et al. [33] applied MLSA to the borreliae.
Using seven different loci (rrs, ﬂa, groEL, hbb, recA, ospA, and
the rrf–rrl spacer), Richter et al. [33] successfully conﬁrmed
the delineation of B. spielmanii, and the results showed excel-
lent correlation with WDDH; also, this approach was less
demanding and thus more robust than DNA–DNA reassocia-
tion methods [33]. As stated above, MLSA has subsequently
been used for the delineation of novel Borrelia species such as
B. spielmanii and B. carolinensis [33,38]. MLSA has subsequently
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been used for the delineation of novel Borrelia species and, in
the recent past, several systems were designed, differing in the
choice of genes. For example, a set of ﬁve loci (rrf–rrl spacer,
rrs, ﬂa, ospA, and p66) was used to clarify the taxonomic status
of 16 uncharacteristic Borrelia isolates [38]. However, for the
most recent delineation of B. kurtenbachii, Margos et al. [42]
used another set of genetic loci (clpA, clpX, nifS, pepX, pyrG,
recG, rplB, and uvrA), all located on the linear chromosome.
Clinical Relevance of Genomic Species
Although the B. burgdorferi sensu lato complex now comprises
up to 18 Borrelia species, only three of them are clearly patho-
genic for humans, namely B. afzelii, B. burgdorferi, and B. garinii
(including B. garinii OspA type 4, recently named B. bavarien-
sis). They can cause localized skin manifestations and dissemi-
nated infection by invading various tissues, including the
nervous system, the joints, and the skin. B. spielmanii was iso-
lated repeatedly from lesional skin of erythema migrans
patients [1]. There are also reports on the isolation or detec-
tion of B. bissettii and B. valaisiana from specimens of patients
suffering from Lyme borreliosis [57,58]. It is, however, unclear
what role B. lusitaniae plays, as the described clinical manifesta-
tions do not match with the known features of Lyme borrelio-
sis [59]. However, the predominant pathogens in central
Europe are B. afzelii and B. garinii (including B. garinii OspA
type 4, recently named B. bavariensis). Among nearly 500 skin
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FIG. 1. The increasing number of genospecies of the Borrelia burgdorferi sensu lato complex. Genospecies that are proven agents of Lyme borrel-
iosis are framed in bold; those suspected of having clinical relevance are framed by a ﬁne line. The colours indicate the geographical areas where
the various genospecies were detected. NA Europe, North America and Europe.
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isolates from patients with erythema migrans in Slovenia, 89%
were identiﬁed as B. afzelii, 11% as B. garinii, and only 0.4% as
B. burgdorferi [1]. According to the detection rates from CSF
of patients suffering from Lyme neuroborreliosis in Europe,
B. garinii is most often the causative agent, followed by B. afzelii
and B. burgdorferi. B. bissettii was isolated only once, and the
presence of B. valaisiana was conﬁrmed in three cases [1].
A comparison of the epidemiological and clinical charac-
teristics of patients with erythema migrans caused by either
B. afzelii or B. garinii yielded 200 consecutive adult patients
with skin isolates of B. afzelii and 53 with isolates of B. garinii.
It was found that B. garinii patients were older, had skin
lesions more often located on the trunk but less often on
the extremities, had shorter incubation and faster evolution
of erythema migrans, more often had local and certain sys-
temic symptoms, more often had abnormal liver function test
results, and more frequently showed seropositivity [60].
In a long-term Slovenian study of adults with culture-con-
ﬁrmed Lyme neuroborreliosis, isolates were similarly identi-
ﬁed as either B. garinii or B. afzelii. It was found that patients
with B. garinii isolated from their CSF had a distinct clinical
presentation from that of patients with B. afzelii. B. garinii
causes what, in Europe, is appreciated as typical early Lyme
neuroborreliosis (Garin–Bujadoux–Bannwarth syndrome),
whereas the clinical features associated with B. afzelii are
much less speciﬁc and more difﬁcult to diagnose [61]. Results
from North America, where B. burgdorferi is the only patho-
genic agent of Lyme borreliosis, showed that, among the sub-
types differentiated by RFLP analysis of the 16S–23S rDNA
intergenic spacer region, there was a predominance of geno-
types 1 and 2 (70%). Similarly, these were much more likely
to cause disseminated infection than genotype 3 isolates [62].
Correlation of B. burgdorferi subtypes with clinical presenta-
tion has been substantiated by others, and might hold the key
to explaining the protean manifestations of Lyme borreliosis
[53]. Although many new species have been described, their
pathogenic role remains questionable. On a cautionary note,
in those exposed to frequent tick bites, exposure to these
newer members of the genus might result in seroreactivity
that could obscure or complicate clinical diagnosis.
The results of a more recent study showed that a distinct
subset of just four of 16 ospC genotypes were responsible
for more than 80% of cases of early disseminated Lyme bor-
reliosis [63].
Conclusions
To date, our understanding of European Lyme borreliosis
has depended on studies undertaken in limited specialist cen-
tres, where clinical isolates can be obtained [60,61,64–67].
To gain more comprehensive insights into the relationships
of genospecies and genotypes of Lyme borreliae with clinical
presentations, it is essential to initiate concerted multicentre
action within Europe.
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